Cover
Cover - shares | 9 Months Ended | |
Sep. 30, 2021 | Nov. 10, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Sep. 30, 2021 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2021 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 000-55413 | |
Entity Registrant Name | Cell Source, Inc. | |
Entity Central Index Key | 0001569340 | |
Entity Tax Identification Number | 32-0379665 | |
Entity Incorporation, State or Country Code | NV | |
Entity Address, Address Line One | 57 West 57th Street | |
Entity Address, Address Line Two | Suite 400 | |
Entity Address, City or Town | New York | |
Entity Address, State or Province | NY | |
Entity Address, Postal Zip Code | 10019 | |
City Area Code | (646) | |
Local Phone Number | 416-7896 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 33,723,554 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Current Assets: | ||
Cash | $ 599,454 | $ 241,619 |
Prepaid expenses | 243,876 | 177,569 |
Other current assets | 17,344 | 29,651 |
Total Current Assets | 860,674 | 448,839 |
Restricted cash | 3,500 | |
Total Assets | 860,674 | 452,339 |
Current Liabilities: | ||
Accounts payable | 285,162 | 193,095 |
Accrued expenses | 949,933 | 1,159,950 |
Accrued expenses - related parties | 101,201 | 198,701 |
Accrued interest | 863,296 | 671,968 |
Accrued interest - related parties | 395,125 | 325,276 |
Accrued compensation | 760,941 | 724,185 |
Advances payable | 195,500 | 195,500 |
Advances payable - related party | 100,000 | 100,000 |
Notes payable | 809,912 | 1,013,000 |
Notes payable - related parties | 150,000 | 150,000 |
Convertible notes payable, net of debt discount of $236,091 and $157,720 as of September 30, 2021 and December 31, 2020, respectively | 5,841,730 | 3,417,836 |
Convertible notes payable - related parties | 225,000 | 225,000 |
Financing liability for directors and officers insurance | 124,581 | |
Accrued dividend payable | 246,192 | 25,210 |
Total Current Liabilities | 11,048,573 | 8,399,721 |
Commitments and contingencies (Note 8) | ||
Stockholders’ Deficiency: | ||
Common Stock, $0.001 par value, 200,000,000 shares authorized; 33,588,578 and 32,538,411 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively | 33,589 | 32,538 |
Additional paid-in capital | 20,120,422 | 17,724,731 |
Accumulated deficit | (30,343,415) | (25,705,993) |
Total Stockholders’ Deficiency | (10,187,899) | (7,947,382) |
Total Liabilities and Stockholders’ Deficiency | 860,674 | 452,339 |
Series A Convertible Preferred Stock [Member] | ||
Stockholders’ Deficiency: | ||
Convertible preferred stock, value | 1,342 | 1,342 |
Series C Convertible Preferred Stock [Member] | ||
Stockholders’ Deficiency: | ||
Convertible preferred stock, value | $ 163 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Convertible preferred stock, par value | $ 0.001 | $ 0.001 |
Convertible preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, shares outstanding | 33,588,578 | 32,538,411 |
Common stock, shares issued | 33,588,578 | 32,538,411 |
Series A Convertible Preferred Stock [Member] | ||
Convertible preferred stock, shares designated | 1,335,000 | 1,335,000 |
Convertible preferred stock, shares issued | 1,342,195 | 1,342,195 |
Convertible preferred stock, shares outstanding | 1,342,195 | 1,342,195 |
Convertible preferred stock liquidation preference | $ 10,294,818 | $ 10,091,672 |
Series C Convertible Preferred Stock [Member] | ||
Convertible preferred stock, shares designated | 500,000 | 500,000 |
Convertible preferred stock, shares issued | 163,296 | 0 |
Convertible preferred stock, shares outstanding | 163,296 | 0 |
Convertible preferred stock liquidation preference | $ 1,242,550 | $ 0 |
Convertible Notes Payable [Member] | ||
Convertible notes payable, net of debt discount | $ 236,091 | $ 157,720 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Operating Expenses: | ||||
Research and development | $ 446,773 | $ 257,546 | $ 1,037,588 | $ 675,017 |
Research and development - related party | 12,500 | 60,475 | 111,667 | |
General and administrative | 856,059 | 908,099 | 2,333,724 | 2,015,624 |
Total Operating Expenses | 1,315,332 | 1,165,645 | 3,431,787 | 2,802,308 |
Loss From Operations | (1,315,332) | (1,165,645) | (3,431,787) | (2,802,308) |
Other (Expense) Income: | ||||
Interest expense | (191,626) | (114,040) | (588,314) | (271,687) |
Interest expense - related parties | (22,805) | (12,827) | (69,849) | (36,708) |
Amortization of debt discount | (269,805) | (146,109) | (547,737) | (190,639) |
Change in fair value of derivative liabilities | 16,977 | |||
Gain on forgiveness of accrued interest | 49,983 | |||
Gain on exchange of accrued interest for common stock | 132,502 | 132,502 | ||
Loss on extinguishment of notes payable | (1,511) | (49,718) | (134,202) | |
Total Other Expense | (484,236) | (141,985) | (1,205,635) | (483,757) |
Net Loss | (1,799,568) | (1,307,630) | (4,637,422) | (3,286,065) |
Dividend attributable to Series A and Series C preferred stockholders | (246,192) | (226,191) | (695,456) | (649,381) |
Net Loss Applicable to Common Stockholders | $ (2,045,760) | $ (1,533,821) | $ (5,332,878) | $ (3,935,446) |
Net Loss Per Common Share - Basic and Diluted | $ (0.06) | $ (0.05) | $ (0.16) | $ (0.13) |
Weighted Average Common Shares Outstanding - | ||||
Basic and Diluted | 33,461,141 | 31,846,661 | 32,897,010 | 30,334,852 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Balance | $ (10,026,910) | $ (9,038,794) | $ (7,947,382) | $ (6,528,017) | $ (6,257,870) | $ (5,741,941) | $ (7,947,382) | $ (5,741,941) |
Series A Convertible Preferred Stock dividends: | ||||||||
Accrual of earned dividends | (246,192) | (225,873) | (223,391) | (226,191) | (211,885) | (211,305) | ||
Payment of dividends in kind | 474,475 | 430,905 | ||||||
Issuance of common stock pursuant to cashless warrant exercise | ||||||||
Issuance of warrants in connection with issuance of convertible notes payable | 226,791 | 37,512 | 196,966 | |||||
Issuance of warrants in connection with exchange of convertible notes payable | 139,728 | |||||||
Warrants issued in satisfaction of accrued interest | 165,216 | 82,350 | ||||||
Stock-based compensation: | ||||||||
Common stock | 70,500 | 2,540 | 317,500 | 6,418 | ||||
Options | 206,400 | 103,600 | ||||||
Warrants | 70,009 | 36,343 | 31,276 | 249,713 | 16,129 | |||
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock | 1,316,158 | |||||||
Conversion of Series C Convertible Preferred Stock into common stock | 50 | |||||||
Warrants modification expense | 29,000 | |||||||
Common stock issued in satisfaction of accrued compensation | 7,097 | 7,097 | ||||||
Issuance of common stock in connection with extension of notes payable | 131,250 | 56,875 | ||||||
Reclassification of derivative liabilities to equity | 345,830 | |||||||
Issuance of warrants in connection with issuance of notes payable | 20,098 | 161,256 | ||||||
Issuance of common stock in exchange of accrued interest | 66,649 | |||||||
Issuance of Series A Convertible Preferred Stock for cash | 603,347 | 25,000 | 100,000 | |||||
Issuance of warrants in connection with issuance of advance payable | 24,386 | |||||||
Net loss | (1,799,568) | (1,313,113) | (1,524,741) | (1,307,630) | (1,164,688) | (813,747) | ||
Series A and C Convertible Preferred Stock dividends: | ||||||||
Balance | (10,187,899) | (10,026,910) | (9,038,794) | (7,018,431) | (6,528,017) | (6,257,870) | (10,187,899) | (7,018,431) |
Preferred Stock [Member] | Series A Convertible Preferred Stock [Member] | ||||||||
Balance | $ 1,342 | $ 1,342 | $ 1,342 | $ 1,261 | $ 1,258 | $ 1,245 | $ 1,342 | $ 1,245 |
Balance, shares | 1,342,195 | 1,342,195 | 1,342,195 | 1,261,749 | 1,258,416 | 1,245,083 | 1,342,195 | 1,245,083 |
Series A Convertible Preferred Stock dividends: | ||||||||
Accrual of earned dividends | ||||||||
Payment of dividends in kind | ||||||||
Issuance of common stock pursuant to cashless warrant exercise | ||||||||
Issuance of warrants in connection with issuance of convertible notes payable | ||||||||
Issuance of warrants in connection with exchange of convertible notes payable | ||||||||
Warrants issued in satisfaction of accrued interest | ||||||||
Stock-based compensation: | ||||||||
Common stock | ||||||||
Options | ||||||||
Warrants | ||||||||
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock | ||||||||
Conversion of Series C Convertible Preferred Stock into common stock | ||||||||
Warrants modification expense | ||||||||
Common stock issued in satisfaction of accrued compensation | ||||||||
Issuance of common stock in connection with extension of notes payable | ||||||||
Reclassification of derivative liabilities to equity | ||||||||
Issuance of warrants in connection with issuance of notes payable | ||||||||
Issuance of common stock in exchange of accrued interest | ||||||||
Issuance of Series A Convertible Preferred Stock for cash | $ 81 | $ 3 | $ 13 | |||||
Issuance of Series A Convertible Preferred Stock for cash, shares | 80,446 | 3,333 | 13,333 | |||||
Issuance of warrants in connection with issuance of advance payable | ||||||||
Net loss | ||||||||
Series A and C Convertible Preferred Stock dividends: | ||||||||
Balance | $ 1,342 | $ 1,342 | $ 1,342 | $ 1,342 | $ 1,261 | $ 1,258 | $ 1,342 | $ 1,342 |
Balance, shares | 1,342,195 | 1,342,195 | 1,342,195 | 1,342,195 | 1,261,749 | 1,258,416 | 1,342,195 | 1,342,195 |
Preferred Stock [Member] | Series C Convertible Preferred Stock [Member] | ||||||||
Balance | ||||||||
Balance, shares | ||||||||
Series A Convertible Preferred Stock dividends: | ||||||||
Accrual of earned dividends | ||||||||
Payment of dividends in kind | ||||||||
Issuance of common stock pursuant to cashless warrant exercise | ||||||||
Issuance of warrants in connection with issuance of convertible notes payable | ||||||||
Issuance of warrants in connection with exchange of convertible notes payable | ||||||||
Warrants issued in satisfaction of accrued interest | ||||||||
Stock-based compensation: | ||||||||
Common stock | ||||||||
Options | ||||||||
Warrants | ||||||||
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock | $ 168 | |||||||
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock, shares | 168,296 | |||||||
Conversion of Series C Convertible Preferred Stock into common stock | $ (5) | |||||||
Conversion of Series C Convertible Preferred Stock into common stock, shares | (5,000) | |||||||
Warrants modification expense | ||||||||
Common stock issued in satisfaction of accrued compensation | ||||||||
Issuance of warrants in connection with issuance of notes payable | ||||||||
Net loss | ||||||||
Series A and C Convertible Preferred Stock dividends: | ||||||||
Balance | $ 163 | $ 163 | ||||||
Balance, shares | 163,296 | 163,296 | ||||||
Common Stock [Member] | ||||||||
Balance | $ 33,301 | $ 32,663 | $ 32,538 | $ 29,699 | $ 27,330 | $ 27,077 | $ 32,538 | $ 27,077 |
Balance, shares | 33,301,564 | 32,663,482 | 32,538,411 | 29,699,509 | 27,329,933 | 27,076,762 | 32,538,411 | 27,076,762 |
Series A Convertible Preferred Stock dividends: | ||||||||
Accrual of earned dividends | ||||||||
Payment of dividends in kind | $ 633 | $ 574 | ||||||
Payment of dividends in kind, shares | 632,677 | 574,576 | ||||||
Issuance of common stock pursuant to cashless warrant exercise | $ 125 | |||||||
Issuance of common stock pursuant to cashless warrant exercise, shares | 125,071 | |||||||
Issuance of warrants in connection with issuance of convertible notes payable | ||||||||
Issuance of warrants in connection with exchange of convertible notes payable | ||||||||
Warrants issued in satisfaction of accrued interest | ||||||||
Stock-based compensation: | ||||||||
Common stock | $ 150 | $ 5 | $ 1,270 | $ 26 | ||||
Common stock, shares | 150,000 | 5,405 | 1,270,000 | 25,671 | ||||
Options | ||||||||
Warrants | ||||||||
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock | $ 72 | |||||||
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock, shares | 71,915 | |||||||
Conversion of Series C Convertible Preferred Stock into common stock | $ 50 | |||||||
Conversion of Series C Convertible Preferred Stock into common stock, shares | 50,000 | |||||||
Warrants modification expense | ||||||||
Common stock issued in satisfaction of accrued compensation | $ 16 | |||||||
Common stock issued in satisfaction of accrued compensation , shares | 15,099 | |||||||
Issuance of common stock in connection with extension of notes payable | $ 525 | $ 227 | ||||||
Issuance of common stock in connection with extension of notes payable, shares | 525,000 | 227,500 | ||||||
Reclassification of derivative liabilities to equity | ||||||||
Issuance of warrants in connection with issuance of notes payable | ||||||||
Issuance of common stock in exchange of accrued interest | $ 266 | |||||||
Issuance of common stock in exchange of accrued interest, shares | 265,534 | |||||||
Issuance of Series A Convertible Preferred Stock for cash | $ 474,475 | |||||||
Issuance of Series A Convertible Preferred Stock for cash, shares | 632,677 | |||||||
Issuance of warrants in connection with issuance of advance payable | ||||||||
Net loss | ||||||||
Series A and C Convertible Preferred Stock dividends: | ||||||||
Balance | $ 33,589 | $ 33,301 | $ 32,663 | $ 29,965 | $ 29,699 | $ 27,330 | $ 33,589 | $ 29,965 |
Balance, shares | 33,588,578 | 33,301,564 | 32,663,482 | 29,965,043 | 29,699,509 | 27,329,933 | 33,588,578 | 29,965,043 |
Additional Paid-in Capital [Member] | ||||||||
Balance | $ 18,482,294 | $ 18,157,935 | $ 17,724,731 | $ 16,565,286 | $ 15,673,117 | $ 15,375,565 | $ 17,724,731 | $ 15,375,565 |
Series A Convertible Preferred Stock dividends: | ||||||||
Accrual of earned dividends | (246,192) | (225,873) | (223,391) | (226,191) | (211,885) | (211,305) | ||
Payment of dividends in kind | 473,842 | 430,331 | ||||||
Issuance of common stock pursuant to cashless warrant exercise | (125) | |||||||
Issuance of warrants in connection with issuance of convertible notes payable | 226,791 | 37,512 | 196,966 | |||||
Issuance of warrants in connection with exchange of convertible notes payable | 139,728 | |||||||
Warrants issued in satisfaction of accrued interest | 165,216 | 82,350 | ||||||
Stock-based compensation: | ||||||||
Common stock | 70,350 | 2,535 | 316,230 | 6,392 | ||||
Options | 206,400 | 103,600 | ||||||
Warrants | 70,009 | 36,343 | 31,276 | 249,713 | 16,129 | |||
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock | 1,315,918 | |||||||
Conversion of Series C Convertible Preferred Stock into common stock | (45) | |||||||
Warrants modification expense | 29,000 | |||||||
Common stock issued in satisfaction of accrued compensation | 7,081 | |||||||
Issuance of common stock in connection with extension of notes payable | 130,725 | 56,648 | ||||||
Reclassification of derivative liabilities to equity | 345,830 | |||||||
Issuance of warrants in connection with issuance of notes payable | 20,098 | 161,256 | ||||||
Issuance of common stock in exchange of accrued interest | 66,383 | |||||||
Issuance of Series A Convertible Preferred Stock for cash | 603,266 | 24,997 | 99,987 | |||||
Issuance of warrants in connection with issuance of advance payable | 24,386 | |||||||
Net loss | ||||||||
Series A and C Convertible Preferred Stock dividends: | ||||||||
Balance | 20,120,422 | 18,482,294 | 18,157,935 | 17,382,155 | 16,565,286 | 15,673,117 | 20,120,422 | 17,382,155 |
Retained Earnings [Member] | ||||||||
Balance | (28,543,847) | (27,230,734) | (25,705,993) | (23,124,263) | (21,959,575) | (21,145,828) | (25,705,993) | (21,145,828) |
Series A Convertible Preferred Stock dividends: | ||||||||
Accrual of earned dividends | ||||||||
Payment of dividends in kind | ||||||||
Issuance of common stock pursuant to cashless warrant exercise | ||||||||
Issuance of warrants in connection with issuance of convertible notes payable | ||||||||
Issuance of warrants in connection with exchange of convertible notes payable | ||||||||
Warrants issued in satisfaction of accrued interest | ||||||||
Stock-based compensation: | ||||||||
Common stock | ||||||||
Options | ||||||||
Warrants | ||||||||
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock | ||||||||
Conversion of Series C Convertible Preferred Stock into common stock | ||||||||
Warrants modification expense | ||||||||
Common stock issued in satisfaction of accrued compensation | ||||||||
Issuance of common stock in connection with extension of notes payable | ||||||||
Reclassification of derivative liabilities to equity | ||||||||
Issuance of warrants in connection with issuance of notes payable | ||||||||
Issuance of common stock in exchange of accrued interest | ||||||||
Issuance of Series A Convertible Preferred Stock for cash | ||||||||
Issuance of warrants in connection with issuance of advance payable | ||||||||
Net loss | (1,799,568) | (1,313,113) | (1,524,741) | (1,307,630) | (1,164,688) | (813,747) | ||
Series A and C Convertible Preferred Stock dividends: | ||||||||
Balance | $ (30,343,415) | $ (28,543,847) | $ (27,230,734) | $ (24,431,893) | $ (23,124,263) | $ (21,959,575) | $ (30,343,415) | $ (24,431,893) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Cash Flows From Operating Activities: | ||
Net loss | $ (4,637,422) | $ (3,286,065) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Change in fair value of derivative liabilities | (16,977) | |
Amortization of debt discount | 547,737 | 190,639 |
Gain on forgiveness of accrued interest | (49,983) | |
Loss on extinguishment of notes payable | 49,718 | 134,202 |
Gain on exchange of accrued interest for common stock | (132,502) | |
Non-cash interest expense - warrants | 286,639 | 60,769 |
Stock-based compensation: | ||
Options | 206,400 | 103,600 |
Warrants | 137,735 | 263,476 |
Common stock | 80,137 | 319,396 |
Changes in operating assets and liabilities: | ||
Prepaid expenses | 254,193 | (72,687) |
Other current assets | 12,307 | 9,355 |
Accounts payable | 92,067 | 240,931 |
Accrued expenses | (210,019) | (46,990) |
Accrued expenses - related parties | (97,500) | (46,597) |
Accrued interest | 369,619 | 207,889 |
Accrued interest - related parties | 2,244 | 2,252 |
Accrued compensation | 36,650 | 51,290 |
Net Cash Used In Operating Activities | (2,919,478) | (2,018,019) |
Cash Flows From Financing Activities: | ||
Proceeds from advances payable | 100,000 | |
Proceeds from issuance of notes payable | 100,000 | |
Proceeds from issuance of convertible notes payable | 3,797,820 | 1,572,500 |
Proceeds from issuance of Series A Preferred Stock | 728,347 | |
Repayment of financing liability | (195,919) | |
Repayment of notes payable | (203,088) | (200,000) |
Repayment of convertible notes payable | (125,000) | (146,000) |
Repayment of advances payable | (110,000) | |
Net Cash Provided By Financing Activities | 3,273,813 | 2,044,847 |
Net Increase In Cash and Restricted Cash | 354,335 | 26,828 |
Cash and Restricted Cash - Beginning of Period | 245,119 | 27,908 |
Cash and Restricted Cash - End of Period | 599,454 | 54,736 |
Cash and restricted cash consisted of the following: | ||
Cash | 599,454 | 54,736 |
Restricted cash | ||
Cash and Restricted cash | 599,454 | 54,736 |
Cash paid for: | ||
Interest | ||
Income taxes | ||
Non-cash investing and financing activities: | ||
Original issue discount in connection with convertible note payable | 58,556 | |
Common stock issued in connection with payment of Series A Convertible Preferred Stock dividends in-kind | 474,475 | |
Conversion of convertible notes payable and accrued interest into Series C Preferred Stock and common stock | 1,316,158 | |
Reclassification of derivative liabilities to equity | 345,830 | |
Conversion of Series C Convertible Preferred Stock into common stock | 50 | |
Issuance of common stock pursuant to cashless warrant exercise | 125 | |
Common stock issued in satisfaction of accrued compensation | 7,097 | |
Financing of Directors and Officer’s insurance | 320,500 | |
Accrued interest converted into notes payable | 41,950 | |
Issuance of warrants in connection with the issuance of notes payable | 461,269 | |
Issuance of warrants in satisfaction of accrued interest | 247,566 | 66,649 |
Accrual of earned preferred stock dividends | (695,456) | (649,381) |
Issuance of placement agent warrants | 10,907 | |
Issuance of common stock as debt discount in in connection with extension of notes payable | 188,125 | |
Repayment of convertible note payable and accrued interest by third party | 100,896 | |
Warrants and conversion options issued in connection with issuance and extension of notes payable | 181,354 | |
Warrants issued in connection with issuance of advance payable | $ 24,386 |
Business Organization, Nature o
Business Organization, Nature of Operations, Risks and Uncertainties and Basis of Presentation | 9 Months Ended |
Sep. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business Organization, Nature of Operations, Risks and Uncertainties and Basis of Presentation | Note 1 - Business Organization, Nature of Operations, Risks and Uncertainties and Basis of Presentation Organization and Operations Cell Source, Inc. (“Cell Source”, “CSI” or the “Company”) is a Nevada corporation formed on June 6, 2012 that is the parent company of Cell Source Limited (“CSL”), a wholly owned subsidiary which was founded in Israel in 2011 in order to commercialize a suite of inventions relating to certain cancer treatments. The Company is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The Company’s lead prospective product is its patented Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. CSL’s Veto Cell immune system management technology is based on technologies patented, owned, and licensed to CSL by Yeda Research and Development Company Limited, an Israeli corporation (“Yeda”) (see Note 8, Commitments and Contingencies Risks and Uncertainties In March 2020, the World Health Organization declared COVID-19, a novel strain of coronavirus, a pandemic. During 2020 and continuing into 2021, the global economy has been, and continues to be, affected by COVID-19. While the Company continues to see signs of economic recovery as certain governments began to gradually ease restrictions, provide economic stimulus and vaccine distribution accelerated, the rate of recovery on a global basis has been affected by resurgence of the virus or its variants in certain jurisdictions causing reinstatement of restrictions in certain jurisdictions. The Company continues to monitor the effects of COVID-19 and its impact on the Company’s operations, financial position, cash flows and its industry in general. The Company considered the impact of COVID-19 on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at September 30, 2021. The full extent of the future impact of COVID-19 on the Company’s operations and financial condition is uncertain. Accordingly, COVID-19 could have a material adverse effect on the Company’s business, results of operations, financial condition and prospects during 2021 and beyond, including the timing and ability of the Company to initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial position of the Company as of September 30, 2021 and the condensed consolidated results of its operations and cash flows for the three and nine months ended September 30, 2021 and 2020. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the operating results for the full year ending December 31, 2021 or any other period. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2020 and for the year then ended which were included in the Company’s Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (“SEC”) on April 15, 2021. |
Going Concern and Management Pl
Going Concern and Management Plans | 9 Months Ended |
Sep. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Going Concern and Management Plans | Note 2 - Going Concern and Management Plans During the nine months ended September 30, 2021, the Company had not generated any revenues, had a net loss of approximately $ 4,637 2,919 10,188,000 30,343 The Company is currently funding its operations on a month-to-month basis. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. The Company’s primary sources of operating funds since inception have been equity and debt financings. Management’s plans include continued efforts to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, if the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 3 - Summary of Significant Accounting Policies Since the date of the Annual Report on Form 10-K for the year ended December 31, 2020, there have been no material changes to the Company’s significant accounting policies. Loss Per Share The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share includes the dilution that would occur upon the exercise or conversion of all dilutive securities into common stock using the “treasury stock” and/or “if converted” methods, as applicable. Weighted average shares outstanding for the three and nine months ended September 30, 2021 and 2020 includes the weighted average impact of warrants to purchase an aggregate of 0 2,043,835 The common stock equivalents associated with the following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Weighted Average Dilutive Common Shares Anti-dilutive September 30, 2021 2020 Options 6,182,004 4,832,004 Warrants 11,201,946 6,250,676 Convertible notes [1] [2] 3,521,885 3,958,756 Convertible preferred stock 15,054,910 13,421,950 Total 35,960,745 28,463,386 [1] Convertible notes are assumed to be converted at the rate of $ 0.75 [2] Excludes shares of common stock underlying convertible notes that are expected to become convertible into shares of Series B Convertible Preferred Stock since such stock had not been designated by the Company as of September 30, 2021. Reclassifications Certain prior period balance sheet amounts have been reclassified to conform to the fiscal 2021 presentation. These reclassifications have no impact on the previously reported net loss. Recently Issued Accounting Standards On May 3, 2021, the Financial Accounting Standards Board (the “FASB”) issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating this new standard and its impact on the Company’s condensed consolidated financial statements and related disclosures. |
Fair Value
Fair Value | 9 Months Ended |
Sep. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value | Note 4 - Fair Value The following table provides a summary of the changes in fair value, including net transfers in and/or out, of all Level 3 liabilities measured at fair value on a recurring basis using unobservable inputs during the nine months ended September 30, 2021: Schedule of Changes in Fair Value of Liabilities Measured at Fair Value on Recurring Basis Accrued Accrued Interest Compensation Total Balance - January 1, 2021 $ 539,836 $ 84,953 $ 624,789 Change in fair value 41,607 97 41,704 Issuance of warrants (82,350 ) - (82,350 ) Balance - March 31, 2021 499,093 85,050 584,143 Change in fair value 37,994 (9 ) 37,985 Accrual of warrant obligation 164,857 - 164,857 Accrual of common stock obligation - 7,097 7,097 Balance - June 30, 2021 701,944 92,138 794,082 Change in fair value 39,012 20 39,032 Issuance of common stock - (7,097 ) (7,097 ) Issuance of warrants (165,216 ) - (165,216 ) Balance - September 30, 2021 $ 575,740 $ 85,061 $ 660,801 Financial liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The Company’s Level 3 liabilities shown in the above table consist of accrued obligations to issue warrants and common stock. In applying the Black-Scholes option pricing model utilized in the valuation of Level 3 liabilities, the Company used the following approximate assumptions: Schedule of Valuation of Level 3 Liabilities For the Three Months Ended For the Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Risk-free interest rate 0.28 0.87 % 0.22 0.28 % 0.28 0.92 % 0.15 1.55 % Expected term (years) 4.00 5.00 4.00 5.00 4.00 5.00 0.52 5.00 Expected volatility 90 % 110 % 90 % 110 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The expected term used is the contractual life of the instrument being valued. Since the Company’s stock does not have significant trading volume, the Company is utilizing an expected volatility based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. As of September 30, 2021 and December 31, 2020, the Company had an obligation to issue 154,495 72,613 See Note 6, Stockholders’ Deficiency – Common Stock and Stock Warrants |
Notes Payable
Notes Payable | 9 Months Ended |
Sep. 30, 2021 | |
Debt Disclosure [Abstract] | |
Notes Payable | Note 5 – Notes Payable As of September 30, 2021 and through the date of this filing, notes and convertible notes payable with principal amounts totaling $ 2,012,162 5,762,162, 250,000 Commitments and Contingencies – Litigation During the three months ended September 30, 2021 and 2020, the Company recorded interest expense of $ 214,431 126,867 269,805 146,109 658,163 308,395 547,737 190,639 1,258,421 997,244 Convertible Notes Payable During the nine months ended September 30, 2021, the Company issued convertible notes payable in the aggregate principal amount of $ 2,297,947 July 7, 2021 March 21, 2022 8 7.50 five 1,868,358 1.25 461,269 On January 28, 2021, the Company issued a convertible note payable in the amount of $ 647,222 July 28, 2021 555,556 13 41,948 8 0.75 The note is convertible at the holder’s option into Series C Preferred Stock at a price of $ 7.50 five 517,778 1.25 106,183 49,718 On March 2, 2021, the Company amended a previously issued convertible note in the principal amount of $ 2,000,000 500,000 2,000,000 4,000,000 five 800,000 1.25 400,000 164,700 4,000,000 1,000,000 4,000,000 6,000,000 five 800,000 164,857 7.50 3,500,000 800,000 165,216 On March 11, 2021, the Company entered into convertible note purchase agreements with two noteholders whereby the Company agreed to repurchase an aggregate of $ 125,000 49,983 49,983 On April 27, 2021, the Company amended the following terms of two convertible notes in the aggregate principal amount of $ 150,000 October 15, 2021 8 10 During the nine months ended September 30, 2021, convertible notes payable in the aggregate principal amount $ 1,262,222 168,296 7.50 53,936 71,915 0.75 Through June 30, 2021, the Company had not designated the Series C Preferred Stock. As a result, the Company did not analyze the notes for a potential beneficial conversion feature as the definition of a firm commitment had not been met since the notes were not yet convertible. On July 26, 2021, the required Certificate of Designation was filed (see Note 6 – Stockholders’ Deficiency – Series C Convertible Preferred Stock). Accordingly, a firm commitment was achieved. The Company analyzed the notes for a beneficial conversion feature and determined that there was none because the notes have an effective conversion price of $ 0.75 per share of underlying common stock, which exceeds the $ 0.47 per share commitment date closing market price of the common stock. Notes Payable During the nine months ended September 30, 2021, the Company paid $ 100,000 150,000 See Note 8, Commitments and Contingencies – Litigation |
Stockholders_ Deficiency
Stockholders’ Deficiency | 9 Months Ended |
Sep. 30, 2021 | |
Equity [Abstract] | |
Stockholders’ Deficiency | Note 6 – Stockholders’ Deficiency Preferred Stock Dividends During the three months ended September 30, 2021 and 2020, the Company accrued additional preferred dividends related to Series A and Series C Preferred Stock of $ 246,192 226,191 695,456 649,381 During the nine months ended September 30, 2021, the Company issued 632,677 0.75 474,475 Series C Convertible Preferred Stock On July 26, 2021, the Company’s Board of Directors approved the designation of 500,000 10,000,000 authorized preferred stock as Series C Convertible Preferred Stock, par value $ 0.001 7.50 Conversion. 7.50 0.75 Mandatory Conversion. Liquidation Preference. Voting Rights. The holders of Series C Preferred Stock have the right to vote on any matter submitted to a vote of holders of common stock, voting together with the common stock as one class, on an as-converted basis. Dividends. Holders of shares of Series C Preferred Stock will be entitled to receive cumulative dividends at an annual rate of 8% During the three months ended September 30, 2021, 5,000 50,000 The Company analyzed the Series C Preferred Stock for a beneficial conversion feature and determined that there was none because the Series C Preferred Stock has an effective conversion price of $ 0.75 per share of underlying common stock, which exceeds the $ 0.47 per share commitment date closing market price of the common stock. See Note 5, Notes Payable – Convertible Notes Payable Common Stock During the nine months ended September 30, 2021, the Company issued 5,405 2,540 During the three months ended September 30, 2021, the Company issued 15,099 7,097 During the three months ended September 30, 2021, the Company issued 150,000 70,500 See Note 5, Notes Payable – Convertible Notes Payable See elsewhere in this note, Stock Warrants Stock Warrants On January 5, 2021, the Company issued 125,000 five 0.95 33,545 During the nine months ended September 30, 2021, the Company issued 125,071 221,275 0.75 During the three months ended September 30, 2021, the Company issued 125,000 five 0.75 36,200 In August 2021, the Company extended the expiration date of a warrant to purchase 75,000 0.75 37,500 0.75 29,000 See Note 5, Notes Payable Stock Options On March 8, 2021, the Company granted 1,350,000 five 750,000 600,000 1.00 218,600 Stock-Based Compensation During the three months ended September 30, 2021, the Company recognized stock-based compensation expense of $ 140,528 70,028 70,009 19 70,500 During the nine months ended September 30, 2021, the Company recognized stock-based compensation expense of $ 424,272 137,735 137,628 107 206,400 80,137 During the three and nine months ended September 30, 2020, the Company recognized stock-based compensation expense of $ 349,050 and $ 686,472 , respectively, related to common stock and warrants, which amounts were included within general and administrative expenses on the condensed consolidated statements of operations. As of September 30, 2021, there was $ 38,471 0.24 |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Sep. 30, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 7 – Related Party Transactions As of September 30, 2021 and December 31, 2020, the Company was required to issue warrants to purchase an aggregate of 1,281,500 1,056,500 0.75 459,000 359,314 291,708 |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 8 – Commitments and Contingencies Yeda Research and License Agreement During the three months September 30, 2021 and 2020, the Company recorded research and development expenses of approximately $ 12,500 0 60,000 112,000 39,419 136,919 MD Anderson Sponsored Research Agreements The Company recognized $ 411,773 and $ 237,546 of research and development expenses during the three months ended September 30, 2021 and 2020, respectively, and $ 925,921 and $ 600,017 of research and development expenses during the nine months ended September 30, 2021 and 2020, respectively, associated with services provided by The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) under the two agreements with MD Anderson dated November 2018 and February 2019, respectively. 211,009 and $ 462,785 , respectively, of accrued research and development expenses pursuant to the agreements with MD Anderson. Subsequent to September 30, 2021, the Company and MD Anderson agreed to extend the Sponsored Research Agreement by one year to November 27, 2022. Under the amendment, the research budget for the additional year is approximately $ 1,300,000 Litigation Certain conditions may exist as of the date the condensed consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company, or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability and an estimate of the range of possible losses, if determinable and material, would be disclosed. In January 2019, the holder of a promissory note in the principal amount of $ 250,000 March 16, 2016 267,680 103,088 146,912 Loss contingencies considered remote are generally not disclosed, unless they involve guarantees, in which case the guarantees would be disclosed. There can be no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. As of September 30, 2021 and December 31, 2020, the Company had not accrued any amounts for contingencies. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 9 – Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Series C Preferred Stock Conversion In October 2021, a holder of Series C Preferred Stock elected to convert 10,000 100,000 Convertible Notes Payable Conversions In November 2021, an aggregate of $ 557,250 of principal outstanding under convertible notes automatically converted into an aggregate of 82,060 shares of Series C Convertible Preferred Stock and the Company elected to pay an aggregate of $ 26,233 of interest accrued under such notes by the issuance of an aggregate of 34,976 shares of common stock. The aggregate note principal had a conversion price of $ 7.50 per share and the common stock was valued at $ 0.75 per share for purposes of the interest payment. See Note 5, Notes Payable Stock Warrants In November 2021, in connection with the conversion of a certain convertible note payable in the principal amount of $ 50,000 five 144,290 1.25 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Loss Per Share | Loss Per Share The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share includes the dilution that would occur upon the exercise or conversion of all dilutive securities into common stock using the “treasury stock” and/or “if converted” methods, as applicable. Weighted average shares outstanding for the three and nine months ended September 30, 2021 and 2020 includes the weighted average impact of warrants to purchase an aggregate of 0 2,043,835 The common stock equivalents associated with the following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Weighted Average Dilutive Common Shares Anti-dilutive September 30, 2021 2020 Options 6,182,004 4,832,004 Warrants 11,201,946 6,250,676 Convertible notes [1] [2] 3,521,885 3,958,756 Convertible preferred stock 15,054,910 13,421,950 Total 35,960,745 28,463,386 [1] Convertible notes are assumed to be converted at the rate of $ 0.75 [2] Excludes shares of common stock underlying convertible notes that are expected to become convertible into shares of Series B Convertible Preferred Stock since such stock had not been designated by the Company as of September 30, 2021. |
Reclassifications | Reclassifications Certain prior period balance sheet amounts have been reclassified to conform to the fiscal 2021 presentation. These reclassifications have no impact on the previously reported net loss. |
Recently Issued Accounting Standards | Recently Issued Accounting Standards On May 3, 2021, the Financial Accounting Standards Board (the “FASB”) issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating this new standard and its impact on the Company’s condensed consolidated financial statements and related disclosures. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Schedule of Weighted Average Dilutive Common Shares Anti-dilutive | The common stock equivalents associated with the following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Weighted Average Dilutive Common Shares Anti-dilutive September 30, 2021 2020 Options 6,182,004 4,832,004 Warrants 11,201,946 6,250,676 Convertible notes [1] [2] 3,521,885 3,958,756 Convertible preferred stock 15,054,910 13,421,950 Total 35,960,745 28,463,386 [1] Convertible notes are assumed to be converted at the rate of $ 0.75 [2] Excludes shares of common stock underlying convertible notes that are expected to become convertible into shares of Series B Convertible Preferred Stock since such stock had not been designated by the Company as of September 30, 2021. |
Fair Value (Tables)
Fair Value (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of Changes in Fair Value of Liabilities Measured at Fair Value on Recurring Basis | The following table provides a summary of the changes in fair value, including net transfers in and/or out, of all Level 3 liabilities measured at fair value on a recurring basis using unobservable inputs during the nine months ended September 30, 2021: Schedule of Changes in Fair Value of Liabilities Measured at Fair Value on Recurring Basis Accrued Accrued Interest Compensation Total Balance - January 1, 2021 $ 539,836 $ 84,953 $ 624,789 Change in fair value 41,607 97 41,704 Issuance of warrants (82,350 ) - (82,350 ) Balance - March 31, 2021 499,093 85,050 584,143 Change in fair value 37,994 (9 ) 37,985 Accrual of warrant obligation 164,857 - 164,857 Accrual of common stock obligation - 7,097 7,097 Balance - June 30, 2021 701,944 92,138 794,082 Change in fair value 39,012 20 39,032 Issuance of common stock - (7,097 ) (7,097 ) Issuance of warrants (165,216 ) - (165,216 ) Balance - September 30, 2021 $ 575,740 $ 85,061 $ 660,801 |
Schedule of Valuation of Level 3 Liabilities | In applying the Black-Scholes option pricing model utilized in the valuation of Level 3 liabilities, the Company used the following approximate assumptions: Schedule of Valuation of Level 3 Liabilities For the Three Months Ended For the Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Risk-free interest rate 0.28 0.87 % 0.22 0.28 % 0.28 0.92 % 0.15 1.55 % Expected term (years) 4.00 5.00 4.00 5.00 4.00 5.00 0.52 5.00 Expected volatility 90 % 110 % 90 % 110 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % |
Going Concern and Management _2
Going Concern and Management Plans (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||
Net Income (Loss) Attributable to Parent | $ 1,799,568 | $ 1,307,630 | $ 4,637,422 | $ 3,286,065 | |
Net Cash Provided by (Used in) Operating Activities | 2,919,478 | $ 2,018,019 | |||
Working capital surplus deficiency | 10,188,000 | 10,188,000 | |||
Accumulated deficit | $ 30,343,415 | $ 30,343,415 | $ 25,705,993 |
Schedule of Weighted Average Di
Schedule of Weighted Average Dilutive Common Shares Anti-dilutive (Details) - shares | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total | 35,960,745 | 28,463,386 | |
Share-based Payment Arrangement, Option [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total | 6,182,004 | 4,832,004 | |
Warrant [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total | 11,201,946 | 6,250,676 | |
Convertible Notes [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total | [1],[2] | 3,521,885 | 3,958,756 |
Convertible Preferred Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total | 15,054,910 | 13,421,950 | |
[1] | Convertible notes are assumed to be converted at the rate of $ 0.75 | ||
[2] | Excludes shares of common stock underlying convertible notes that are expected to become convertible into shares of Series B Convertible Preferred Stock since such stock had not been designated by the Company as of September 30, 2021. |
Schedule of Weighted Average _2
Schedule of Weighted Average Dilutive Common Shares Anti-dilutive (Details) (Parenthetical) | Sep. 30, 2021$ / shares |
Accounting Policies [Abstract] | |
Debt Instrument, Convertible, Conversion Price | $ 0.75 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details Narrative) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Accounting Policies [Abstract] | ||||
Weighted average impact of warrants | 0 | 2,043,835 | 0 | 2,043,835 |
Schedule of Changes in Fair Val
Schedule of Changes in Fair Value of Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Inputs, Level 3 [Member] - Fair Value, Recurring [Member] - USD ($) | 3 Months Ended | ||
Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Balance, ending | $ 794,082 | $ 584,143 | $ 624,789 |
Change in fair value | 39,032 | 41,704 | |
Issuance of warrants | (165,216) | (82,350) | |
Change in fair value | 37,985 | ||
Accrual of warrant obligation | 164,857 | ||
Accrual of common stock obligation | 7,097 | ||
Issuance of common stock | (7,097) | ||
Balance, ending | 660,801 | 794,082 | 584,143 |
Accrued Interest [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Balance, ending | 701,944 | 499,093 | 539,836 |
Change in fair value | 39,012 | 41,607 | |
Issuance of warrants | (165,216) | (82,350) | |
Change in fair value | 37,994 | ||
Accrual of warrant obligation | 164,857 | ||
Accrual of common stock obligation | |||
Issuance of common stock | |||
Balance, ending | 575,740 | 701,944 | 499,093 |
Accrued Compensation [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Balance, ending | 92,138 | 85,050 | 84,953 |
Change in fair value | 20 | 97 | |
Issuance of warrants | |||
Change in fair value | (9) | ||
Accrual of warrant obligation | |||
Accrual of common stock obligation | 7,097 | ||
Issuance of common stock | (7,097) | ||
Balance, ending | $ 85,061 | $ 92,138 | $ 85,050 |
Schedule of Valuation of Level
Schedule of Valuation of Level 3 Liabilities (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Measurement Input, Option Volatility [Member] | ||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||
Fair value measurement input, percentage | 0.90 | 1.10 | 0.90 | 1.10 |
Measurement Input, Expected Dividend Rate [Member] | ||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||
Fair value measurement input, percentage | 0 | 0 | 0 | 0 |
Minimum [Member] | ||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||
Risk free interest rate | 0.28% | 0.22% | 0.28% | 0.15% |
Expected term (Years) | 4 years | 4 years | 4 years | 6 months 7 days |
Maximum [Member] | ||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||
Risk free interest rate | 87.00% | 0.28% | 0.92% | 1.55% |
Expected term (Years) | 5 years | 5 years | 5 years | 5 years |
Fair Value (Details Narrative)
Fair Value (Details Narrative) - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2021 | Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | ||
Number of common stock shares issued for sevice | 154,495 | 154,495 |
Value of common stock shares issued for service | $ 72,613 | $ 72,613 |
Notes Payable (Details Narrativ
Notes Payable (Details Narrative) - USD ($) | Apr. 27, 2021 | Mar. 11, 2021 | Jan. 28, 2021 | Jan. 28, 2021 | Jan. 05, 2021 | Jan. 31, 2019 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Jul. 26, 2021 | Jun. 18, 2021 | Mar. 02, 2021 | Dec. 31, 2020 |
Short-term Debt [Line Items] | ||||||||||||||||
Notes Payable, Current | $ 809,912 | $ 809,912 | $ 1,013,000 | |||||||||||||
Debt discount | $ 269,805 | $ 146,109 | $ 547,737 | $ 190,639 | ||||||||||||
Debt principal amount | $ 250,000 | |||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ 0.75 | $ 0.75 | ||||||||||||||
Debt Instrument, Maturity Date | Mar. 16, 2016 | |||||||||||||||
Repayment of convertible notes payable | $ 125,000 | 146,000 | ||||||||||||||
Repayments of Notes Payable | 203,088 | 200,000 | ||||||||||||||
Note Holder [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Debt principal amount | $ 150,000 | 150,000 | ||||||||||||||
Repayments of Notes Payable | 100,000 | |||||||||||||||
Convertible Note Purchase Agreements [Member] | Two Note Holders [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Repayment of convertible notes payable | $ 125,000 | |||||||||||||||
Notes payable | $ 49,983 | |||||||||||||||
Forgivness of accrued interest | 49,983 | |||||||||||||||
Warrant [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Interest expense | $ 29,000 | $ 29,000 | ||||||||||||||
Warrant [Member] | Note Holder [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 221,275 | 221,275 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.95 | $ 0.75 | $ 0.75 | |||||||||||||
Fair Value Adjustment of Warrants | $ 33,545 | |||||||||||||||
Common Stock [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Interest Payable | $ 53,936 | |||||||||||||||
Shares Issued, Price Per Share | 0.75 | $ 0.75 | $ 0.75 | |||||||||||||
Stock Issued During Period, Shares, New Issues | 71,915 | |||||||||||||||
Common Stock Convertible Conversion Price | 0.75 | $ 0.75 | ||||||||||||||
Commitment date closing market price | $ 0.47 | $ 0.47 | $ 0.47 | |||||||||||||
Notes Payable [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Notes Payable, Current | $ 2,012,162 | $ 2,012,162 | ||||||||||||||
Convertible Notes Payable, Current | 5,762,162 | 5,762,162 | ||||||||||||||
Interest expense | 214,431 | 126,867 | 658,163 | 308,395 | ||||||||||||
Debt discount | 269,805 | $ 146,109 | 547,737 | $ 190,639 | ||||||||||||
Accrued interest and penalties related to notes payable | 1,258,421 | 1,258,421 | $ 997,244 | |||||||||||||
Past Due Notes Payable [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Notes Payable, Current | 250,000 | 250,000 | ||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Debt principal amount | $ 2,297,947 | $ 2,297,947 | $ 4,000,000 | $ 2,000,000 | ||||||||||||
Debt Instrument, Maturity Date Range, Start | Jul. 7, 2021 | |||||||||||||||
Debt Instrument, Maturity Date Range, End | Mar. 21, 2022 | |||||||||||||||
Warrants and Rights Outstanding, Term | 5 years | 5 years | 5 years | 5 years | 5 years | 5 years | ||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 517,778 | 517,778 | 1,868,358 | 800,000 | 800,000 | 1,868,358 | 400,000 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.25 | $ 1.25 | $ 1.25 | $ 1.25 | $ 1.25 | |||||||||||
Fair Value Adjustment of Warrants | $ 106,183 | $ 164,857 | $ 164,700 | $ 461,269 | ||||||||||||
Interest Payable | 1,262,222 | |||||||||||||||
Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost | 49,718 | |||||||||||||||
Proceeds from Issuance of Debt | 1,000,000 | 500,000 | ||||||||||||||
Long-term Debt, Gross | $ 3,500,000 | $ 3,500,000 | ||||||||||||||
Convertible Notes Payable [Member] | Warrant [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 800,000 | 800,000 | ||||||||||||||
Fair Value Adjustment of Warrants | $ 165,216 | |||||||||||||||
Convertible Notes Payable [Member] | Minimum [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Debt Instrument, Increase (Decrease), Net | 4,000,000 | 2,000,000 | ||||||||||||||
Convertible Notes Payable [Member] | Maximum [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Debt Instrument, Increase (Decrease), Net | $ 6,000,000 | $ 4,000,000 | ||||||||||||||
Convertible Notes Payable [Member] | Series C Preferred Stock [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Notes accrue interest rate | 8.00% | 8.00% | ||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ 7.50 | $ 7.50 | ||||||||||||||
Stock Issued During Period, Shares, New Issues | 168,296 | |||||||||||||||
Convertible Notes Payable [Member] | Series B Convertible Preferred Stock [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ 7.50 | $ 7.50 | $ 7.50 | |||||||||||||
Convertible Notes Payable One [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Interest Payable | $ 647,222 | |||||||||||||||
Debt Instrument, Maturity Date | Jul. 28, 2021 | |||||||||||||||
Convertible Notes Payable Two [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Debt principal amount | $ 555,556 | $ 555,556 | ||||||||||||||
Notes accrue interest rate | 13.00% | 13.00% | ||||||||||||||
Interest Payable | $ 41,948 | $ 41,948 | ||||||||||||||
New Note [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Notes accrue interest rate | 8.00% | 8.00% | ||||||||||||||
Shares Issued, Price Per Share | $ 0.75 | $ 0.75 | ||||||||||||||
New Note [Member] | Series C Preferred Stock [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Shares Issued, Price Per Share | $ 7.50 | $ 7.50 | ||||||||||||||
Preferred Stock, Conversion Basis | The note is convertible at the holder’s option into Series C Preferred Stock at a price of $7.50 per share and automatically converts into Series C Convertible Preferred Stock on the maturity date. | |||||||||||||||
Convertible Notes Two [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Debt principal amount | $ 150,000 | |||||||||||||||
Debt Instrument, Maturity Date | Oct. 15, 2021 | |||||||||||||||
Convertible Notes Two [Member] | Minimum [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Notes accrue interest rate | 8.00% | |||||||||||||||
Convertible Notes Two [Member] | Maximum [Member] | ||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||
Notes accrue interest rate | 10.00% |
Stockholders_ Deficiency (Detai
Stockholders’ Deficiency (Details Narrative) - USD ($) | Jul. 26, 2021 | Mar. 08, 2021 | Jan. 05, 2021 | Sep. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Aug. 31, 2021 | Dec. 31, 2020 |
Class of Stock [Line Items] | ||||||||||||
Fair value of common stock issued | $ 603,347 | $ 25,000 | $ 100,000 | |||||||||
Preferred stock shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | ||||||||
Preferred stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||
Debt instrument, conversion price | $ 0.75 | $ 0.75 | ||||||||||
Stock-based compensation expense | $ 140,528 | 349,050 | $ 424,272 | $ 686,472 | ||||||||
Expense related to warrants | 70,028 | 137,735 | 263,476 | |||||||||
Warrant expense included within stockholder's deficiency | 70,009 | 137,628 | ||||||||||
Accrued compensation | 19 | 107 | ||||||||||
Expense related to options | 70,500 | 206,400 | 103,600 | |||||||||
Expense related to common stock | 80,137 | 319,396 | ||||||||||
Unrecognized share based compensation | $ 38,471 | $ 38,471 | ||||||||||
Unrecognized share based compensation weighted average period | 2 months 26 days | |||||||||||
Equity Option [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Grant date fair value of options | $ 218,600 | |||||||||||
Consultants [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
common stock issued | 15,099 | |||||||||||
Fair value of common stock issued | $ 7,097 | |||||||||||
Consultants One [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
common stock issued | 150,000 | |||||||||||
Fair value of common stock issued | $ 70,500 | |||||||||||
Chief Executive Officer [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Option granted for services | 750,000 | |||||||||||
Chief Executive Officer [Member] | Equity Incentive Plan [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Options vesting term | 5 years | |||||||||||
Option granted for services | 1,350,000 | |||||||||||
Option exercise price | $ 1 | |||||||||||
Director [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,281,500 | 1,281,500 | 1,056,500 | |||||||||
Option granted for services | 600,000 | |||||||||||
Common Stock [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
common stock issued | 632,677 | |||||||||||
Shares Issued, Price Per Share | $ 0.75 | $ 0.75 | $ 0.75 | |||||||||
Fair value of common stock issued | $ 474,475 | |||||||||||
Shares issued upon conversion | 50,000 | |||||||||||
Commitment date market price | $ 0.47 | $ 0.47 | $ 0.47 | |||||||||
Vested number of shares | 5,405 | |||||||||||
Grant date fair value of options | $ 2,540 | |||||||||||
Issued shares of common stock pursuant to a cashless warrant | 125,071 | |||||||||||
Common Stock Convertible Conversion Price | $ 0.75 | $ 0.75 | ||||||||||
Expense related to common stock | $ 80,137 | |||||||||||
Warrant [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Incremental Expense | $ 29,000 | $ 29,000 | ||||||||||
Warrant [Member] | August 4, 2021 to August 4, 2025 [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 75,000 | |||||||||||
Common Stock Convertible Conversion Price | $ 0.75 | |||||||||||
Warrant [Member] | August 26, 2021 to August 26, 2025 [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 37,500 | |||||||||||
Warrant exercise price per share | $ 0.75 | |||||||||||
Warrant [Member] | Consultants [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 125,000 | 125,000 | ||||||||||
Options vesting term | 5 years | |||||||||||
Warrant exercise price per share | $ 0.75 | $ 0.75 | ||||||||||
Fair value of warrants | $ 36,200 | |||||||||||
Warrant [Member] | Note Holder [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 125,000 | |||||||||||
Options vesting term | 5 years | |||||||||||
Warrant exercise price per share | $ 0.95 | $ 0.75 | $ 0.75 | |||||||||
Fair value of warrants | $ 33,545 | |||||||||||
Issued shares of common stock pursuant to a cashless warrant | 125,071 | |||||||||||
Warrants purchase for common stock | 221,275 | 221,275 | ||||||||||
Warrant [Member] | Director [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Warrant exercise price per share | $ 0.75 | $ 0.75 | ||||||||||
Series A and Series C Preferred Stock [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Additional preferred dividends | $ 246,192 | $ 226,191 | $ 695,456 | $ 649,381 | ||||||||
Series C Convertible Preferred Stock [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Preferred stock shares authorized | 500,000 | |||||||||||
Preferred stock, par value | $ 0.001 | |||||||||||
Debt instrument, conversion price | $ 0.75 | $ 0.75 | $ 0.75 | |||||||||
Preferred stock voting rights, description | The holders of Series C Preferred Stock have the right to vote on any matter submitted to a vote of holders of common stock, voting together with the common stock as one class, on an as-converted basis. | |||||||||||
Preferred Stock, Dividend Payment Terms | Holders of shares of Series C Preferred Stock will be entitled to receive cumulative dividends at an annual rate of 8% of the stated value. Dividends are payable semi-annually on June 30 and December 31, commencing on December 31, 2022 | |||||||||||
Preferred Stock, Dividend Rate, Percentage | 8.00% | |||||||||||
Number of shares converted | 5,000 | |||||||||||
Series C Preferred Stock [Member] | ||||||||||||
Class of Stock [Line Items] | ||||||||||||
Preferred stock, par value | $ 7.50 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - Director [Member] - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||
Warrants purchase for common stock | 1,281,500 | 1,056,500 |
Loan amount | $ 459,000 | |
Accrued interest - related parties | $ 359,314 | $ 291,708 |
Warrant [Member] | ||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | ||
Warrant exercise price per share | $ 0.75 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - USD ($) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 9 Months Ended | |||||
Oct. 31, 2019 | Jan. 31, 2019 | Nov. 15, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Nov. 30, 2021 | Dec. 31, 2020 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Research and development expenses | $ 446,773 | $ 257,546 | $ 1,037,588 | $ 675,017 | |||||
Accrued research and development expenses | 949,933 | 949,933 | $ 1,159,950 | ||||||
Debt Instrument, Face Amount | $ 250,000 | ||||||||
Debt Instrument, Maturity Date | Mar. 16, 2016 | ||||||||
Litigation Settlement, Amount Awarded from Other Party | $ 267,680 | ||||||||
Repayments of Notes Payable | 203,088 | 200,000 | |||||||
Repayments of Related Party Debt | 146,912 | ||||||||
Court Officer [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Repayments of Notes Payable | 103,088 | ||||||||
Subsequent Event [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Debt Instrument, Face Amount | $ 557,250 | ||||||||
Yeda Research and License Agreement [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Research and development expenses | 12,500 | 0 | 60,000 | 112,000 | |||||
Accrued research and development expenses | 39,419 | 39,419 | 136,919 | ||||||
MD Anderson Sponsored Research Agreements [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Research and development expenses | 411,773 | $ 237,546 | 925,921 | $ 600,017 | |||||
Accrued research and development expenses | $ 211,009 | $ 211,009 | $ 462,785 | ||||||
MD Anderson Sponsored Research Agreements [Member] | Subsequent Event [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
[custom:AgreementPeriodDescription] | Subsequent to September 30, 2021, the Company and MD Anderson agreed to extend the Sponsored Research Agreement by one year to November 27, 2022. | ||||||||
[custom:ResearchBudget-0] | $ 1,300,000 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | Nov. 30, 2021 | Oct. 21, 2021 | Sep. 30, 2021 | Sep. 30, 2021 | Jul. 26, 2021 | Jan. 31, 2019 |
Subsequent Event [Line Items] | ||||||
Debt Instrument, Face Amount | $ 250,000 | |||||
Debt Instrument, Convertible, Conversion Price | $ 0.75 | $ 0.75 | ||||
Common Stock [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Stock Issued During Period, Shares, New Issues | 632,677 | |||||
Shares Issued, Price Per Share | $ 0.75 | $ 0.75 | $ 0.75 | |||
Subsequent Event [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Debt Instrument, Face Amount | $ 557,250 | |||||
Interest Payable | $ 26,233 | |||||
Stock Issued During Period, Shares, New Issues | 34,976 | |||||
Debt Instrument, Convertible, Conversion Price | $ 7.50 | |||||
Shares Issued, Price Per Share | $ 0.75 | |||||
Convertible notes payable | $ 50,000 | |||||
Share-based payment award vesting period | 5 years | |||||
Purchase of warrants | 144,290 | |||||
Warrant exercise price per share | $ 1.25 | |||||
Subsequent Event [Member] | Common Stock [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Number of shares converted | 100,000 | |||||
Series C Convertible Preferred Stock [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Number of shares converted | 5,000 | |||||
Debt Instrument, Convertible, Conversion Price | $ 0.75 | $ 0.75 | $ 0.75 | |||
Series C Convertible Preferred Stock [Member] | Subsequent Event [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Number of shares converted | 82,060 | 10,000 |